Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially as Rybelsus(R). According to … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive interim results from a human pilot study currently underway evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, which is … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology … Continue reading →

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment of diabetes and weight loss. DehydraTECH has demonstrated, in many … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced plans to launch new human and animal studies that seek to examine its patented DehydraTECH(TM) technology’s potential on GLP-1 drugs for the treatment of diabetes and weight … Continue reading →

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. “Lexaria’s IND submission builds on five previous human … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest global, exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology. This license will allow SulfoSyn to use Lexaria’s technology in non-pharmaceutical uses of … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX) is a global innovator and biotechnology company focused on developing technology that enhances the bioavailability of multiple fat-soluble active molecules and active pharmaceutical ingredients (“APIs”). The company’s flagship technology is the patented DehydraTECH(TM) drug delivery technology, which … Continue reading →

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus … Continue reading →